 |
12 Diseases |  |
0 Trials |
|
0 Trials |  |
30 News |  |
- || patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD), lumretuzumab (RG7116) / Roche, seribantumab (MM-121) / Elevation Oncology
Review, Journal: The Therapeutic Significance of HER3 in Non-small Cell Lung Cancer (NSCLC): A Review Study. (Pubmed Central) - Jan 17, 2024
Additionally, antibody-drug conjugates (ADCs) like HER3-DXd (patritumab deruxtecan) are new drug candidates that have demonstrated selective delivery of cytotoxic chemicals to NSCLC cells by exploiting HER3's widespread expression, minimizing cytotoxicity. This review aims to evaluate the efficacy of current HER3 therapeutics in development and their therapeutic potential in NSCLC, incorporating evidence from clinical trials.
- || lumretuzumab (RG7116) / Roche
Enrollment change, Combination therapy, Metastases: A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin (clinicaltrials.gov) - Jan 30, 2017
P1a/1b, N=145, Completed, Sponsor: Hoffmann-La Roche
This review aims to evaluate the efficacy of current HER3 therapeutics in development and their therapeutic potential in NSCLC, incorporating evidence from clinical trials. N=184 --> 145
- ||| lumretuzumab (RG7116) / Roche, Perjeta (pertuzumab) / Roche
Trial completion, Enrollment change: A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein (clinicaltrials.gov) - Jan 30, 2017
P1, N=66, Completed, Sponsor: Hoffmann-La Roche
N=184 --> 145 Active, not recruiting --> Completed | N=35 --> 66
- lumretuzumab (RG7116) / Roche
Phase classification, Combination therapy, Metastases: A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology (clinicaltrials.gov) - Dec 20, 2016
P1/2, N=12, Terminated, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | N=35 --> 66 Phase classification: P1 --> P1/2
- lumretuzumab (RG7116) / Roche
Enrollment change, Trial termination, Trial primary completion date, Combination therapy, Metastases: A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology (clinicaltrials.gov) - Dec 19, 2016
P1, N=12, Terminated, Sponsor: Hoffmann-La Roche
Phase classification: P1 --> P1/2 N=53 --> 12 | Suspended --> Terminated | Trial primary completion date: Dec 2015 --> Mar 2016
- lumretuzumab (RG7116) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Trial primary completion date: A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein (clinicaltrials.gov) - Jul 5, 2016
P1, N=35, Active, not recruiting, Sponsor: Hoffmann-La Roche
N=53 --> 12 | Suspended --> Terminated | Trial primary completion date: Dec 2015 --> Mar 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2017 --> Nov 2016
- ||| lumretuzumab (RG7116) / Roche
Trial completion, Phase classification, Trial primary completion date, Combination therapy, Metastases: A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin (clinicaltrials.gov) - Jun 2, 2016
P1a/1b, N=184, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2017 --> Nov 2016 Active, not recruiting --> Completed | Phase classification: P1 --> P1a/1b | Trial primary completion date: May 2016 --> Feb 2016
- lumretuzumab (RG7116) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date: A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein (clinicaltrials.gov) - Feb 2, 2016
P1, N=40, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | Phase classification: P1 --> P1a/1b | Trial primary completion date: May 2016 --> Feb 2016 Trial primary completion date: Mar 2017 --> Jul 2017
- || lumretuzumab (RG7116) / Roche
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin (clinicaltrials.gov) - Nov 10, 2015
P1, N=184, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Mar 2017 --> Jul 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2016 --> May 2016
- lumretuzumab (RG7116) / Roche
Trial primary completion date, Combination therapy, Metastases: A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology (clinicaltrials.gov) - Sep 24, 2015
P1, N=53, Suspended, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2016 --> May 2016 Trial primary completion date: Aug 2018 --> Dec 2015
- ||| lumretuzumab (RG7116) / Roche
Enrollment open, Combination therapy, Metastases: A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin (clinicaltrials.gov) - Sep 3, 2015
P1, N=182, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Aug 2018 --> Dec 2015 Active, not recruiting --> Recruiting
- | lumretuzumab (RG7116) / Roche
Trial suspension, Combination therapy, Metastases: A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology (clinicaltrials.gov) - Aug 13, 2015
P1, N=53, Suspended, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Recruiting Recruiting --> Suspended
- lumretuzumab (RG7116) / Roche
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin (clinicaltrials.gov) - Jul 6, 2015
P1, N=183, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Suspended Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Jan 2016
- || lumretuzumab (RG7116) / Roche
Trial primary completion date, Combination therapy, Metastases: A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology (clinicaltrials.gov) - Feb 24, 2015
P1, N=53, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Jan 2016 Trial primary completion date: Aug 2018 --> Nov 2016
- || lumretuzumab (RG7116) / Roche
Trial primary completion date, Combination therapy, Metastases: A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology (clinicaltrials.gov) - Feb 6, 2015
P1, N=53, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Aug 2018 --> Nov 2016 Trial primary completion date: Nov 2016 --> Aug 2018
- lumretuzumab (RG7116) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date: A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein (clinicaltrials.gov) - Jan 28, 2015
P1, N=40, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Nov 2016 --> Aug 2018 Trial primary completion date: Nov 2016 --> Apr 2017
- || lumretuzumab (RG7116) / Roche
Trial primary completion date, Combination therapy, Metastases: A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin (clinicaltrials.gov) - Jan 28, 2015
P1, N=182, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Nov 2016 --> Apr 2017 Trial primary completion date: Aug 2015 --> Nov 2015
- lumretuzumab (RG7116) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date: A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein (clinicaltrials.gov) - Nov 25, 2014
P1, N=40, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Aug 2015 --> Nov 2015 Trial primary completion date: Feb 2017 --> Nov 2016
- lumretuzumab (RG7116) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date: A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein (clinicaltrials.gov) - Nov 12, 2014
P1, N=40, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Feb 2017 --> Nov 2016 Trial primary completion date: Nov 2016 --> Feb 2017
- ||| lumretuzumab (RG7116) / Roche
Enrollment open, Combination therapy, Metastases: A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology (clinicaltrials.gov) - Oct 17, 2014
P1, N=53, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Nov 2016 --> Feb 2017 Not yet recruiting --> Recruiting
- lumretuzumab (RG7116) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date: A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein (clinicaltrials.gov) - Aug 21, 2014
P1, N=40, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2015 --> Nov 2016
- ||| lumretuzumab (RG7116) / Roche
New P1 trial, Combination therapy, Metastases: A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology (clinicaltrials.gov) - Jul 30, 2014
P1, N=53, Not yet recruiting, Sponsor: Hoffmann-La Roche
- || lumretuzumab (RG7116) / Roche
Trial primary completion date, Combination therapy, Metastases: A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin (clinicaltrials.gov) - Jun 27, 2014
P1, N=160, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Sep 2015 --> Nov 2016 Trial primary completion date: Jan 2016 --> Aug 2015
- || lumretuzumab (RG7116) / Roche
Enrollment change, Combination therapy, Metastases: A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin (clinicaltrials.gov) - Apr 7, 2014
P1, N=160, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Jan 2016 --> Aug 2015 N=105 --> 160
- | lumretuzumab (RG7116) / Roche, Perjeta (pertuzumab) / Roche
New P1 trial: A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein (clinicaltrials.gov) - Aug 5, 2013
P1, N=40, Recruiting, Sponsor: Hoffmann-La Roche
- lumretuzumab (RG7116) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open: A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein (clinicaltrials.gov) - Aug 5, 2013
P1, N=40, Recruiting, Sponsor: Hoffmann-La Roche
N=105 --> 160 Not yet recruiting --> Recruiting
- ||| lumretuzumab (RG7116) / Roche
Enrollment open, Combination therapy, Metastases: A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin (clinicaltrials.gov) - Jan 3, 2012
P1, N=160, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| lumretuzumab (RG7116) / Roche
New P1 trial, Combination therapy, Metastases: A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin (clinicaltrials.gov) - Nov 28, 2011
P1, N=160, Recruiting, Sponsor: Hoffmann-La Roche